spironolactone has been researched along with transforming growth factor beta in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (56.25) | 29.6817 |
| 2010's | 13 (40.63) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E | 1 |
| Bobadilla, NA; Feria, I; Gamba, G; García-Torres, R; González, MA; Juárez, P; López-Casillas, F; Pichardo, I; Ramírez, V; Uribe, N | 1 |
| Bloem, LJ; Chun, TY; Pratt, JH | 1 |
| Fujisawa, G; Fujita, N; Ishibashi, S; Itabashi, N; Kusano, E; Muto, S; Okada, K | 1 |
| Aizawa, Y; Kodama, M; Ma, M; Tachikawa, H; Takahashi, T; Wahed, MI; Watanabe, K; Yamaguchi, K | 1 |
| Chun, TY; Pratt, JH | 1 |
| Iso, Y; Katagiri, T; Sato, T; Suzuki, H; Takeyama, Y; Wakabayashi, K | 1 |
| Aldigier, JC; Brown, NJ; Fogo, AB; Kanjanbuch, T; Ma, LJ | 1 |
| Kobayashi, N; Matsuoka, H; Nakano, S; Ohno, T; Yoshida, K | 1 |
| Asano, Y; Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Minamino, T; Okada, K; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H; Tsukamoto, O; Yamasaki, S; Yulin, L | 1 |
| Blanco, JA; Bobadilla, NA; Bonventre, JV; Cruz, C; Gamba, G; Pérez-Rojas, J; Trujillo, J; Uribe, N; Vaidya, VS | 1 |
| Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V | 1 |
| Inagaki, K; Makino, H; Miyoshi, T; Mukai, T; Ogura, T; Otani, H; Otsuka, F; Suzuki, J; Takeda, M | 1 |
| Fujita, T; Goto, A; Kobayashi, N; Matsuoka, H; Onozato, ML; Tojo, A | 1 |
| Iga, I; Kobara, M; Murakami, M; Murata, S; Nakata, T; Serizawa, R; Taira, M; Toba, H | 1 |
| Cha, DR; Han, JY; Han, KH; Han, SY; Kang, YS; Kim, HK; Ko, GJ; Lee, MH; Song, HK | 1 |
| Carvajal, CA; Castillo, CR; Contreras, FJ; Fardella, CE; Herrada, AA; Kalergis, AM; Mosso, LM; Stehr, CB | 1 |
| Hayashi, T; Kimura, S; Kitada, K; Kitaura, Y; Kobayashi, K; Kurumazuka, D; Matsuda, H; Matsumoto, C; Matsumura, Y; Mori, T; Shirakawa, H | 1 |
| Abd El Motteleb, DM; Abd El-Aziz, TA; Abdel-Aziz, HR; Mohamed, RH | 1 |
| Gillespie, BW; Govani, SM; Higgins, PD; Johnson, LA; Joyce, JC; Waljee, AK | 1 |
| Barrera-Chimal, J; Bobadilla, NA; Gamba, G; Pérez-Villalva, R; Reyna, J; Rodríguez-Romo, R; Uribe, N | 1 |
| Geier, A; Happ, K; Jahn, D; Link, S; Queisser, N; Schupp, N; Zimnol, A | 1 |
| Bozfakioglu, S; Caliskan, Y; Ecder, T; Gorgulu, N; Gursu, M; Kazancioglu, R; Ozturk, S; Telci, A; Yazici, H; Yelken, B | 1 |
| El-Moselhy, MA; Hofni, A; Khalifa, MM; Taye, A | 1 |
| Higgins, PD; Huang, S; Johnson, LA; Rodansky, ES; Spence, JR | 1 |
| Cai, J; Chen, L; Chen, X; Gao, Z; Gong, Y; Huang, W; Zhang, H; Zhou, H; Zhou, X | 1 |
| Chen, S; Guo, Z; Liu, J; Xi, D; Zhao, J; Zhou, H | 1 |
| Cai, J; Chen, L; Chen, X; Zheng, G; Zhou, H; Zhou, X | 1 |
| Donderski, R; Grajewska, M; Manitius, J; Miśkowiec, I; Odrowąż-Sypniewska, G; Siódmiak, J; Stefańska, A; Stróżecki, P; Sulikowska, B | 1 |
| Gong, H; Li, H; Lu, Y; Ma, X; Wang, B; Wang, C; Wu, Z; Yan, Y; Zhang, X | 1 |
| Balochnejadmojarrad, T; Chamani, E; Ebadi, Z; Fadaei, R; Fallah, S; Kazemi Fard, T; Moradi, N | 1 |
| Aljohmani, AI; Alzoubi, KH; Mayyas, FA | 1 |
32 other study(ies) available for spironolactone and transforming growth factor beta
| Article | Year |
|---|---|
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan | 2001 |
Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity.
Topics: Aldosterone; Animals; Chronic Disease; Collagen Type I; Collagen Type IV; Cyclosporine; Fibronectins; Immunosuppressive Agents; Kidney; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Rats; Rats, Wistar; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes.
Topics: Aldosterone; Animals; Animals, Newborn; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Gene Expression Regulation; Glucocorticoids; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Hypertrophy; Immunohistochemistry; Kidney; Male; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Rats; Rats, Sprague-Dawley; Spironolactone; Staining and Labeling; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2004 |
Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy.
Topics: Animals; Autoimmune Diseases; Cardiomyopathy, Dilated; Collagen Type III; Dose-Response Relationship, Drug; Electrocardiography; Eplerenone; Fibrosis; Hemodynamics; Male; Mineralocorticoid Receptor Antagonists; Myocarditis; Myocardium; Rats; Rats, Inbred Lew; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Ventricular Dysfunction, Left; Ventricular Remodeling | 2005 |
Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes.
Topics: Aldosterone; Animals; Cell Line; Gene Expression Regulation; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Plasminogen Activator Inhibitor 1; Rats; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
Eplerenone suppresses neointimal formation after coronary stent implantation in swine.
Topics: Actins; Administration, Oral; Animals; Blood Vessel Prosthesis Implantation; Collagen Type I; Collagen Type III; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Eplerenone; Fibrosis; Hyperplasia; Immunohistochemistry; Macrophages; Male; Mineralocorticoid Receptor Antagonists; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Stents; Swine; Time Factors; Transforming Growth Factor beta; Tunica Intima | 2006 |
Regression of existing glomerulosclerosis by inhibition of aldosterone.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Diuretics; Glomerulonephritis; Kidney Function Tests; Losartan; Male; Nephrectomy; Proteinuria; Rats; Rats, Sprague-Dawley; Spironolactone; Transcription, Genetic; Transforming Growth Factor beta | 2005 |
Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinas
Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Chemokine CCL2; Coronary Vessels; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibrillar Collagens; Gene Expression; Heart Ventricles; Hypertension; Imidazolidines; Intracellular Signaling Peptides and Proteins; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Peptidyl-Dipeptidase A; Phosphorylation; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Scavenger Receptors, Class E; Signal Transduction; Sodium Chloride; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2005 |
The antagonism of aldosterone receptor prevents the development of hypertensive heart failure induced by chronic inhibition of nitric oxide synthesis in rats.
Topics: Actins; Aldosterone; Animals; Blotting, Western; Cytochrome P-450 CYP11B2; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Heart Ventricles; Hypertension; Immunohistochemistry; Male; Mineralocorticoid Receptor Antagonists; NF-kappa B; NG-Nitroarginine Methyl Ester; Nitric Oxide; Peptide Fragments; Proliferating Cell Nuclear Antigen; Protein Precursors; Random Allocation; Rats; Rats, Inbred WKY; Receptors, Mineralocorticoid; RNA, Messenger; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity.
Topics: Animals; Apoptosis; Arterioles; Blood Pressure; Body Weight; Caspase 3; Cell Adhesion Molecules; Cyclosporine; Fibrosis; Immunosuppressive Agents; In Situ Nick-End Labeling; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Male; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Potassium; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA; Spironolactone; Transforming Growth Factor beta | 2007 |
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan | 2006 |
Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation.
Topics: Aldosterone; Animals; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Protein Receptors, Type I; Bone Morphogenetic Proteins; Cell Line; Cell Proliferation; Enzyme Activation; Eplerenone; Extracellular Signal-Regulated MAP Kinases; JNK Mitogen-Activated Protein Kinases; Mesangial Cells; Mice; Mineralocorticoid Receptor Antagonists; Mitogen-Activated Protein Kinases; Mitosis; Phosphorylation; Signal Transduction; Smad6 Protein; Spironolactone; Transforming Growth Factor beta | 2007 |
Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiac Output, Low; Drug Synergism; Eplerenone; Hypertension; Indoles; Kidney; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidases; Oxidative Stress; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Sodium-Potassium-Exchanging ATPase; Spironolactone; Superoxide Dismutase; Transforming Growth Factor beta | 2007 |
Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Topics: Animals; Collagen Type I; Collagen Type IV; Cytochrome P-450 CYP11B2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fibrosis; Gene Expression Regulation, Enzymologic; Kidney; Ligation; Male; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Nephrectomy; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Renal Artery; Renin-Angiotensin System; RNA, Messenger; Spironolactone; Transforming Growth Factor beta | 2008 |
Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Base Sequence; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; DNA Primers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Eplerenone; Extracellular Matrix Proteins; Gene Expression; Glomerular Filtration Rate; In Vitro Techniques; Male; Mesangial Cells; Mineralocorticoid Receptor Antagonists; Plasminogen Activator Inhibitor 1; Rats; Rats, Inbred OLETF; Renin-Angiotensin System; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2009 |
Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha.
Topics: Adult; Aldosterone; Cross-Sectional Studies; Female; Humans; Hyperaldosteronism; Hypertension; Interleukin-10; Male; Middle Aged; Renin; Renin-Angiotensin System; Spironolactone; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2009 |
Dietary salt restriction activates mineralocorticoid receptor signaling in volume-overloaded heart failure.
Topics: Aldosterone; Animals; Atrial Natriuretic Factor; Body Weight; Cell Size; Contraindications; Diet, Sodium-Restricted; Endomyocardial Fibrosis; Heart; Heart Failure; Hemodynamics; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Organ Size; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Transforming Growth Factor beta; Tyrosine; Ventricular Remodeling | 2009 |
Effect of RAS inhibition on TGF-β, renal function and structure in experimentally induced diabetic hypertensive nephropathy rats.
Topics: Animals; Drug Therapy, Combination; Hypertension, Renal; Kidney; Kidney Function Tests; Male; Nephritis; Random Allocation; ras Proteins; Rats; Rats, Wistar; Spironolactone; Tetrahydroisoquinolines; Transforming Growth Factor beta | 2013 |
Spironolactone and colitis: increased mortality in rodents and in humans.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Colitis; Crohn Disease; Female; Fibrosis; Hospitalization; Humans; Inflammation; Intestinal Diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Myofibroblasts; Rats; Retrospective Studies; Spironolactone; Survival Rate; Transforming Growth Factor beta; Trinitrobenzenesulfonic Acid | 2012 |
Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury.
Topics: Acute Kidney Injury; Animals; Collagen Type I; Disease Models, Animal; Diuretics; Dose-Response Relationship, Drug; Fibronectins; Ischemia; Kidney; Male; Mineralocorticoid Receptor Antagonists; Oxidative Stress; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Spironolactone; Transforming Growth Factor beta | 2013 |
Aldosterone induces fibrosis, oxidative stress and DNA damage in livers of male rats independent of blood pressure changes.
Topics: Aldosterone; Animals; Blood Pressure; Blotting, Western; Cyclic N-Oxides; Histocytochemistry; Liver Cirrhosis; Male; Mineralocorticoid Receptor Antagonists; NF-E2-Related Factor 2; Oxidative Stress; Random Allocation; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA; Spin Labels; Spironolactone; Statistics, Nonparametric; Transforming Growth Factor beta | 2014 |
Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients.
Topics: Adult; Aged; Biomarkers; CA-125 Antigen; Connective Tissue Growth Factor; Diuretics; Female; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis; Peritoneum; Spironolactone; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A; Young Adult | 2014 |
Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclooxygenase 2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Inflammation; Kidney; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Protective Agents; Rats; Rats, Wistar; Spironolactone; Streptozocin; Superoxides; Tetrazoles; Transforming Growth Factor beta | 2014 |
Intestinal organoids: a model of intestinal fibrosis for evaluating anti-fibrotic drugs.
Topics: Actins; Calcium-Binding Proteins; Cell Differentiation; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Embryonic Stem Cells; Fibronectins; Fibrosis; Humans; Intestines; Myofibroblasts; Myosin-Light-Chain Kinase; Organoids; Pluripotent Stem Cells; Spironolactone; Trans-Activators; Transforming Growth Factor beta | 2015 |
Protective Effect of Spironolactone on Endothelial-to-Mesenchymal Transition in HUVECs via Notch Pathway.
Topics: Epithelial-Mesenchymal Transition; Gene Expression; Human Umbilical Vein Endothelial Cells; Humans; Platelet Endothelial Cell Adhesion Molecule-1; Receptors, Notch; Signal Transduction; Spironolactone; Transforming Growth Factor beta; Vimentin | 2015 |
Spirolactone provides protection from renal fibrosis by inhibiting the endothelial-mesenchymal transition in isoprenaline-induced heart failure in rats.
Topics: Animals; Epithelial-Mesenchymal Transition; Heart Failure; Kidney Diseases; Rats; Spironolactone; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2016 |
Anti-Fibrosis Effect of Relaxin and Spironolactone Combined on Isoprenaline-Induced Myocardial Fibrosis in Rats via Inhibition of Endothelial-Mesenchymal Transition.
Topics: Actins; Animals; Antigens, CD; Cadherins; Cardiotonic Agents; Collagen Type I; Collagen Type III; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Endomyocardial Fibrosis; Epithelial-Mesenchymal Transition; Human Umbilical Vein Endothelial Cells; Humans; Isoproterenol; Male; Myocardium; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Sprague-Dawley; Relaxin; Spironolactone; Transforming Growth Factor beta; Vimentin | 2017 |
Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Biomarkers; Blood Pressure; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Echocardiography; Female; Fibrosis; Humans; Inflammation; Interleukin-6; Male; Matrix Metalloproteinase 2; Middle Aged; Mineralocorticoid Receptor Antagonists; Osteopontin; P-Selectin; Parathyroid Hormone; Peritoneal Dialysis; Pulse Wave Analysis; Renal Insufficiency, Chronic; Spironolactone; Thrombosis; Transforming Growth Factor beta; Vascular Stiffness | 2017 |
Mineralocorticoid receptor antagonism protects the aorta from vascular smooth muscle cell proliferation and collagen deposition in a rat model of adrenal aldosterone-producing adenoma.
Topics: ACTH-Secreting Pituitary Adenoma; Aldosterone; Animals; Antihypertensive Agents; Aorta; Cell Proliferation; Collagen; Disease Models, Animal; Eplerenone; Hydralazine; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Proto-Oncogene Proteins c-mdm2; Random Allocation; Rats, Sprague-Dawley; Spironolactone; Transforming Growth Factor beta; Vascular Remodeling; Vasodilator Agents | 2018 |
Captopril and Spironolactone Can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting microRNA-192 and microRNA-29a/b/c.
Topics: Animals; Antihypertensive Agents; Blood Glucose; Blood Urea Nitrogen; Captopril; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diuretics; Drug Combinations; Drug Repositioning; Gene Expression Regulation; Hyperglycemia; Hypoglycemic Agents; Male; MicroRNAs; Rats; Rats, Wistar; Spironolactone; Streptozocin; Transforming Growth Factor beta; Treatment Outcome | 2019 |
The Impact of Spironolactone on Markers of Myocardial Oxidative Status, Inflammation and Remodeling in Hyperthyroid Rats.
Topics: Aldosterone; Animals; Antioxidants; Biomarkers; Blood Pressure; Body Weight; Cardiovascular Diseases; Endothelin-1; Heart; Heart Rate; Hyperthyroidism; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Nitrites; Organ Size; Oxidative Stress; Random Allocation; Rats; Spironolactone; Thyroid Hormones; Thyroxine; Transforming Growth Factor beta | 2020 |